Vita Life Sciences (ASX:VLS) Total Receivables: A$13.64 Mil (As of Dec. 2025)


ASX:VLS Vita Life Sciences Ltd ASX:VLS
85 GF Score
Price A$2.45
GF Value A$2.48
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Vita Life Sciences Total Receivables?

Vita Life Sciences ASX:VLS -2.00% 85 Total Receivables is A$13.64 Mil as of Dec. 2025. GuruFocus rates ASX:VLS with a GF Score™ of 85/100 and a GF Value™ of A$2.48 (Fairly Valued). The stock has 1 warning sign investors should review.

Vita Life Sciences's Total Receivables for the quarter that ended in Dec. 2025 was A$13.64 Mil.

Vita Life Sciences Total Receivables Related Terms

Vita Life Sciences Total Receivables Historical Data

* Premium members only.

The historical data trend for Vita Life Sciences's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vita Life Sciences Total Receivables Chart

Vita Life Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.12 8.98 11.22 12.00 13.64

Vita Life Sciences Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.22 12.34 12.00 13.41 13.64
ASX:VLS
85GF Score
Vita Life Sciences Ltd ASX:VLS
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vita Life Sciences Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of A$13.64 Mil mean?
Vita Life Sciences (ASX:VLS) has a Total Receivables of A$13.64 Mil as of Dec. 2025. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Vita Life Sciences and its competitors.
Is Vita Life Sciences' Total Receivables too high?
Vita Life Sciences' current Total Receivables is A$13.64 Mil. Overall, Vita Life Sciences has a GF Score™ of 85/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vita Life Sciences' Total Receivables compare to ZTS?
Vita Life Sciences' Total Receivables of A$13.64 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Drug Manufacturers company?
A good Total Receivables depends on the Drug Manufacturers industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Vita Life Sciences and its competitors. Vita Life Sciences's current Total Receivables is A$13.64 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vita Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Vita Life Sciences (ASX:VLS) is currently considered Fairly Valued. The stock's GF Value™ is A$2.48, compared to a current price of A$2.45 — trading 1.2% below its estimated fair value. The current Total Receivables is A$13.64 Mil. Vita Life Sciences' overall GF Score™ is 85/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Vita Life Sciences (ASX:VLS), the current Total Receivables is A$13.64 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vita Life Sciences (ASX:VLS) Overvalued in 2026?

Based on GuruFocus' analysis, Vita Life Sciences stock appears to be undervalued. The current stock price of A$2.45 is trading 1.2% below its estimated GF Value™ of A$2.48. GuruFocus considers Vita Life Sciences to be Fairly Valued.

Key valuation signals for ASX:VLS:

  • Total Receivables: A$13.64 Mil
  • GF Value™: A$2.48 vs. price of A$2.45 (1.2% below fair value)
  • GF Score™: 85/100 with 1 warning sign

No single metric tells the full story. See the ASX:VLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vita Life Sciences Business Description

Address 1-5 Chalmers Crescent, Suite 802, Level 8, Mascot, Sydney, NSW, AUS, 2020
Vita Life Sciences Ltd is an Australian-based pharmaceutical and healthcare company involved in formulating, packaging, selling, and distributing vitamins and supplements. It produces a wide range of premium supplements, vitamins, minerals, herbs, and superfoods catered to all age categories and health conditions. The company markets its products through pharmacies and health food stores under the VitaHealth, VitaScience, and Herbs of Gold brands throughout the Asia-Pacific region. Vita Life Sciences has two operating segments: VMS Operational, which generates maximum revenue, and VMS Investments. Geographically, the Group generates maximum revenue from Malaysia and Singapore, and the rest from Australia, and China and Vietnam.
85GF Score

Get the complete analysis for ASX:VLS

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.45
Price
A$2.48
GF Value